Arai, M., Yoguchi, A., Takizawa, T., Yokoyama, T., Kanda, T., Kurabayashi, M. and Nagai, R. (2000) Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca2q-ATPase gene transcription.Circ. Res. 86, 8-14.
Araki, M., Hasegawa, K., Iwai-Kanai, E., Fujita, M., Sawamura, T., Kakita, T., Wada, H., Morimoto, T. and Sasayama, S.(2000) Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes.
J Am Coll Cardiol. 36,1411-8.
Bertheau, P., Plassa, F., Espie, M., Turpin, E., de Roquancourt, A., Marty, M., Lerebours, F., Beuzard, Y., Janin, A. and de The, H. (2002) Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
Lancet 360,852-854.
Bezombes, C., de Thonel, A., Apostolou, A., Louat, T., Jaffrezou, J.P., Laurent, G. and Quillet-Mary, A. (2002) Overexpression of protein kinase Czeta confers protection against antileukemic drugs by inhibiting the redox- dependent sphingomyelinase activation. Mol Pharmacol 62,1446-1455.
Binaschi, M., Bigioni, M., Cipollone, A., Rossi, C., Goso, C., Maggi, C.A., Capranico, G. and Animati, F. (2001) Anthracyclines: selected new developments. Curr Med Chem1,113-130.
Binaschi, M., Capranico, G., Dal Bo, L., and Zunino, F. (1997) Relationship between lethal effects and topoisomerase II mediated double-strand DNA breaks produced by anthracyclines with different sequence specificity. Mol Pharmacol 51,1053-1059.
Binaschi, M., Farinosi, R., Borgnetto, M.E. and Capranico, G. (2000) In vivo
II-poisoning anthracyclines.Cancer Res 60,3770-3776.
Boucek Jr., R.J., Buck, S.H., Scott, F., Oquist, N.L., Fleischer, S.and Olson, R.D. (1993) Anthracycline-induced tension in permeabilized cardiac fibers: evidence for the activation of the calcium release channel of sarcoplasmic reticulum. J. Mol. Cell. Cardiol. 25, 249-259.
Boucek Jr., R.J., Dodd, D.A., Atkinson, J.B., Oquist, N. and Olson, R.D.(
1997) Contractile failure in chronic doxorubicin-induced cardiomyopathy.
J. Mol. Cell. Cardiol. 29, 2631-2640.
Boucek Jr., R.J., Olson, R.D., Brenner, D.E., Ogunbunmi, E.M., Inui, M. and Fleischer, S. (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J. Biol. Chem. 262,15851-15856.
Caroni, P., Villani, F. and Carafoli, E. (1981) The cardiotoxic antibiotic doxorubicin inhibits the NaqrCa2q exchange of dog heart sarcolemmal vesicles. FEBS Lett. 130, 184-186.
Chao, H.H., Chen, J.J., Chen, C.H., Lin, H., Cheng, C.F., Lian, W.S., Chen, Y.L., Juan, S.H., Liu, J.C., Liou, J.Y., Chan, P. and Cheng, T.H. (2005) Inhibition of angiotensin II induced endothelin-1 gene expression by 17-beta-oestradiol in rat cardiac fibroblasts. Heart. 91,664-9.
Cheng, C.M., Hong, H.J., Liu, J.C., Shih, N.L., Juan, S.H., Loh, S.H., Chan, P., Chen, J.J. and Cheng, T.H. (2003a) Crucial role of extracellular signal- regulated kinase pathway in reactive oxygen species-mediated endothelin-1 gene expression induced by endothelin-1 in rat cardiac fibroblasts. Mol Pharmacol. 63,1002-11.
Cheng, T.H., Cheng, P.Y., Shih, N.L., Chen, I.B., Wang, D.L. and Chen, J.J.
(2003b) Involvement of reactive oxygen species in angiotensin II-induced
endothelin-1 gene expression in rat cardiac fibroblasts. J Am Coll Cardiol.
42,1845-54.
Cheng, T.H., Shih, N.L., Chen, S.Y., Loh, S.H., Cheng, P.Y., Tsai, C.S., Liu, S.H., Wang, D.L. and Chen, J.J. (2001) Reactive oxygen species mediate cyclic strain-induced endothelin-1 gene expression via Ras/Raf/extracellular signal-regulated kinase pathway in endothelial cells. J Mol Cell Cardiol.
33,1805-14.
Clementi, M.E., Giardina, B., Di Stasio, E., Mordente, A. and Misiti, F. (2003) Doxorubicinderived metabolites induce release of cytochrome c and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res 23,2445–2450.
Cutts SM, Swift LP, Rephaeli A, Nudelman A, and Phillips DR (2003) Sequence specificity of adriamycin-DNA adducts in human tumor cells. Mol Cancer Ther 2:661–670.
Danesi, R., Del, T.M., Bernardini, C. and Penco, S. (1987) Exogenous doxorubicinol induces cardiotoxic effects in rats. Eur. J. Cancer Clin.Oncol.
23, 907–913.
Doi, Y., Ozaka, T., Fukushige, H., Yoshizuka, M. and Fujimoto, S. (1996) Increase in number of Weibel-Palade bodies and endothelin-1 release from endothelial cells in the cadmium-treated rat thoracic aorta. Virchows Arch.
428,367-373.
Doroshow, J.H., Synold, T.W., Somlo, G., Akman, S.A. and Gajewski, E. (2001) Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood 97,2839–2845.
Nielsen, D., Maare, C. and Skovsgaard, T. (1996) Cellular Resistance to
Duchman, S.M., Thohan, V., Kalra, D. and Torre-Amione, G. (2000) Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure. Curr Opin Cardiol. 15,136-40.
Gariboldi, M.B., Ravizza, R., Riganti, L., Meschini, S., Calcabrini, A., Marra, M., Arancia, G., Dolfini, E. and Monti, E. (2003) Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. Int J Oncol 22,1057-1064.
Gille, L. and Nohl, H. (1997) Analyses of the molecular mechanism of adriamycininduced cardiotoxicity. Free Radic Biol Med 23,775-782.
Glannessi,D., Delry,S. and Vitale, RL.(2001)The role of endothelins and their receptors in heart failure.Pharmacological Research. 43,111-126.
Goldie, R.G.(1999)Endothelins in health and disease: an overview.Clin Exp Pharmacol Physiol. 26,145-8.
Goormaghtigh, E. and Ruysschaert, J.M.(1984) Anthracycline glycoside–
membrane interactions. Biochim. Biophys. Acta 779, 271-88.
Green, P.S. and Leeuwenburgh, C. (2002) Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta 1588,94-101.
Hsu, Y.H., Chen, J.J., Chang, N.C., Chen, C.H., Liu, J.C., Chen, T.H., Jeng, C.J., Chao, H.H. and Cheng, T.H. (2004)Role of reactive oxygen species-sensitive extracellular signal-regulated kinase pathway in angiotensin II-induced endothelin-1 gene expression in vascular endothelial cells.J Vasc Res.
41,64-74.
Inoue, A., Narumi, K., Matsubara, S., Sugawara, S., Saijo, Y., Satoh, K. and Nukiwa, T. (2000) Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung
cancer cells irrespective of the status of p53 gene. Cancer Lett 157,105-112.
Jaruga, P. and Dizdaroglu, M. (1996) Repair of products of oxidative DNA base damage in human cells. Nucleic Acids Res 24,1389-1394.
Jun-ichi, A. and Bradford C. B.(1998) Reactive oxygen species as mediators of signal transductionin cardiovascular disease. Trends Cardiovasc. Med.
8,59–64.
Kakinuma, Y. Miyauchi, T., Yuki, K., Murakoshi, N., Goto, K. and Yamaguchi, I.
(2000) Mitochondrial dysfunction of cardiomyocytes causing impairment of cellular energy metabolism induces apoptosis, and concomitant increase in cardiac endothelin-1 expression. J Cardiovasc Pharmacol. 36,S201-4.
Kang, J.V., Zhou, Z.X., Wang, G.W. Buridi, A. and Klein, J.B. (2000)
Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem 275,13690-13698.
Kastan, M.B.,Onyekwere, O.,Sidransky, D., Vogelstein, B. and Craig, R.W.
(1991) Participation of p53 in the cellular response to DNA damage.Cancer Res 51,6304-6311.
Kendall B. Wallace (2003) Doxorubicin-induced cardiac mitochondrionopathy . Pharmacology & Toxicology 93, 105.
Kim, R., Tanabe, K., Uchida, Y., Emi, M., Inoue, H. and Toge, T. (2002) Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 50,343-352.
Kim, Y., Ma, A.G., Kitta, K., Fitch, S.N., Ikeda, T., Ihara, Y., Simon, A.R., Evans, T. and Suzuki, Y.J. (2003) Anthracycline-induced suppression of
myocyte apoptosis. Mol Pharmacol 63,368-377.
Kotamraju, S., Chitambar, C.R., Kalivendi, S.V., Joseph, J. and Kalyanaraman, B. (2002) Transferrin receptor-dependent iron uptake is responsible for doxorubicin mediated apoptosis in endothelial cells: role of oxidant-induced iron uptake is responsible for doxorubicinmediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem 277,17179-17187.
Laurent, G. and Jaffrezou, J.P. (2001) Signaling pathways activated by daunorubicin.Blood 98,913-924.
Licata, S., Saponiero, A., Mordente, A. and Minotti, G. (2000) Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 13,414-420.
Ling, Y.H., Priebe, W. and Perez-Solar, R. (1993) Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug resistant cells. Cancer Res 53, 1845–1852.
Macarthur, H., Warner, T.D.,Wood, E.G.,Corder, R. and Vane, J.R. (1994) Endothlin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch.Biochem. Biophys. Res.
Commun. 200,395-400.
Marnett, L.J., Riggins, J.N. and West, J.D. (2003) Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein.
J Clin Investig 111,583-593.
Martin, D., Salinas, M., Fujita, N., Tsuruo, T. and Cuadrado, A. (2002) Ceramide and reactive oxygen species generated by 277,42943-42952.
Mima, T., Mostafa, M.G. (2001) Inhibition of overexpression of endothelin-1 by an RNA synthesis inhibitor, doxorubicin, in the rat vasospasm model. Acta
Neurochir Suppl. 77,221-3.
Minotti, G., Cairo, G. and Monti, E. (1999) Role of iron in anthracycline cardiotoxicity:new tunes for an old song? FASEB J 13,199-212.
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. and Gianni, L. (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 56,185-229.
Minotti, G., Ronchi, R., Salvatorelli, E., Menna, P. and Cairo, G .(2001) Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res
61,8422-8428.
Miyashita, T. and Reed, J.C. (1998) Tumor suppressor p53 is a direct transcription activator of the human bax gene. Cell 80:293–299.
Miyauchi, T., Sakai, S. and Sugishita, Y.(1997)Myocardial endothelin-1 plays a good role and an aggravating role in the failing heart in rats with chronic heart failure. Circulation. 96,2746.
Mostafa, M.G., Mima, T., Taniguchi, T. and Mori, K. (2000) Doxorubicin, an RNA synthesis inhibitor, prevents vasoconstriction and inhibits aberrant expression of endothelin-1 in the cerebral vasospasm model of the rat.
Neurosci Lett. 283,197-200.
Mulder, P., Richard, V., Derumeaux, G., Hogie, M., Henry, J.P., Lallemand, F.,, Compagnon, P., Mace, B., Comoy, E., Letac, B. and Thuillez, C. (1997)Role of endogenous endothelin in chronic heart failure: effect of long-term H2O2 induce caspase-3-independent degradation of Akt/protein kinase B.
Circulation. 96,1976-82.
Chronic vascular toxicity of doxorubicin in an organ-cultured artery.Br J Pharmacol. 132,1365-73.
Negoro, S., Oh, H., Tone, E., Kunisada, K., Fujio, Y., Walsh, K., Kishimoto, T.
and Yamauchi-Takihara, K. (2001) Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 103,555-561.
Niedernhofer, L.J., Daniels, J.S., Rouzer, C.A., Greene, R.E. and Marnett, L.J.
(2003) Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J Biol Chem 278, 31426-31433.
Ogata, Y., Takahashi, M., Ueno, S., Takeuchi, K., Okada, T., Mano, H., Ookawara, S., Ozawa, K., Berk, B.C., Ikeda, U., Shimada, K. and Kobayashi, E. (2003)Antiapoptotic effect of endothelin-1 in rat cardiomyocytes in vitro.
Hypertension. 41,1156-63.
Ohhara, H., Kanaide, H. and Nakamura, M.(1981) A protective effect of coenzyme Q10 on the adriamycin-induced cardiotoxicity in the isolated perfused rat heart. J. Mol. Cell. Cardiol. 13, 741-752.
Olson, H.M., Young, D.M., Prieur, D.J., LeRoy, A.F. and Reagan, R.L.(
1974) Electrolyte and morphologic alterations of myocardium in adriamycin - treated rabbits. Am. J. Pathol. 77, 439-454.
Olson, R.D., Boerth, R.C., Gerber, J.G. and Nies, A.S. (1981) Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci. 29, 1393-1401.
Olson, R.D. and Mushlin, P.S. (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. see comments. FASEB J. 4, 3076-3086.
Olson, R.D., Mushlin, P.S., Brenner, D.E., Fleischer, S., Cusack, B.J.,Chang,
B.K. and Boucek Jr., R.J. (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Natl. Acad. Sci. U.S. A. 85,3585-3589.
Ondrias, K., Borgatta, L., Kim, D.H. and Ehrlich, B.E. (1990) Biphasic effects of doxorubicin on the calcium release channel from sarcoplasmic reticulum of cardiac muscle. Circ. Res. 67, 1167-1174.
Ortega Mateo, A. and de Artinano, A.A.(1997) Highlights on endothelins: a review. Pharmacol Res. 36,339-51.
Ozaka, T., Doi, Y., Kayashima, K. and Fujimoto, S. (1997) Weibel-Palade bodies as a storage site of calcitonin gene-related peptide and endothelin-1 in blood vessels of the rat carotid body. Anat.Rec.247,388-394.
Penault-Llorca, F., Cayre, A., Bouchet Mishellany, F., Amat, S., Feillel, V., Le Bouedec, G., Ferriere, J.P., De Latour, M. and and Chollet, P. (2003) Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22,1319-1325.
Perego, P., Corna, E., De Cesare, M., Gatti, L., Polizzi, D., Pratesi, G., Supino, R. and Zunino, F. (2001) Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem 8,31-37.
Peters, J.H., Gordon, G.R., Kashiwase, D. and Acton, E.M.(1981) Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin. Cancer Chemother. Pharmacol. 7, 65-69.
Ruiz-Ruiz, C., Robledo, G., Cano, E., Redondo, J.M. and Lopez-Rivas, A.
(2003) Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells. J Biol Chem 278,31667-31675.
synthesis.Br J Pharmacol. 126,391-8.
Sakai, S., Miyauchi, T., Kobayashi, M., Yamaguchi, I., Goto, K. and Sugishita, Y.(1996) Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 384,353-5.
Sayed-Ahmed, M.M., Khattab, M.M., Gad, M.Z. and Osman, A.M. (2001) Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin- induced cardiomyopathy. Pharmacol Toxicol. 89,140-4.
Schams, D., Berisha,B., Neuvians, T., Amselgruber, W., and Kraetzl, W.D.
(2003) Real-time changes of the local vasoactive peptide systems (angiotensin, endothelin) in the bovine corpus luteum after induced luteal regression.Molecular reproduction and development 65,57–66.
Sirvio, M.L., Helin, K., Stewen, P., Tikkanen, I. and Fyhrquist, F. (1997) Endothelin-1 in heart and pulmonary tissue in experimental heart failure.
Blood Press. 6,250-5.
Stearns, V., Singh, B., Tsangaris, T., Crawford, J.G., Novielli, A., Ellis, M.J., Isaacs, C., Pennanen, M., Tibery, C. and Farhad, A. (2003) A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9,124-133.
Suzuki, T. and Miyauchi, T. (2001) A novel pharmacological action of ET-1 to prevent the cytotoxicity of do more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells. J Med Chem 41,1306-1314.
Taatjes, D.J., Fenick, D.J. and Koch, T.H. (1999) Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines. Chem Res Toxicol 12,588-596.
Taatjes, D.J., Gaudiano, G., Resing, K. and Koch, T.H. (1997) Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J Med Chem 40,1276-1286.
Taatjes, D.J. and Koch, T.H. (2001) Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells. Curr Med Chem 8,15-29.
Takahiko, S. and Takashi, M. (2001) A novel pharmacological action of ET-1 to prevent the cytotoxicity of doxorubicin in cardiomyocytes. Am J Physiol Regulatory Integrative Comp. Physiol. 280, R1399–R1406.
Tokudome, T., Horio, T., Fukunaga, M., Okumura, H., Hino, J., Mori, K., Yoshihara, F., Suga, S., Kawano, Y., Kohno, M. and Kangawa, K.(2004) Ventricular nonmyocytes inhibit doxorubicin-induced myocyte apoptosis:
involvement of endogenous endothelin-1 as a paracrine factor. Endocrinology.
145,2458-66.
Tonnessen, T., Christensen, G., Oie, E., Holt, E., Kjekshus, H., Smiseth, O.A., Sejersted, O.M. and Attramadal, H. (1997)Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats. Cardiovasc Res.
33,601-10.
Vasquez-Vivar, J., Martasek, P., Hogg, N., Masters, B.S., Pritchard, K.A. Jr, and Kalyanaraman, B. (1997) Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 36,11293-11297.
Wallace, K.B.(2003) Doxorubicin-induced cardiac mitochondrionopathy.
Pharmacology & Toxicology 93, 105–115.
Wang, L., Ma, W., Markovich, R., Chen, J.W. and Wang, P.H. (1998a)
factor I. Circ Res 83,516-522.
Wang, L., Ma, W., Markovich, R., Lee, W.L., and Wang, P.H. (1998b) Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells.Endocrinology 139,1354-1360.
Wu, W., Lee, W.L., Wu, Y.Y., Chen, D., Liu, T.J., Jang, A., Sharma, P.M., and Wang, P.H. (2000) Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells.
J Biol Chem 275,40113-40119.
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. and Masaki, T.(1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332,411-5.
Yamashita, J., Ogawa, M. and Nomura, K. (1994)Plasma endothelin-1 and doxorubicin cardiotoxicity. N Engl J Med. 331,1528-9.
Yamashita, J., Ogawa, M. and Shirakusa, T. (1995)Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int J Cancer. 62,542-7.
Young, C.W. and Raymond, V. (1986) Clinical assessment of the structure–
activity relationship of anthracyclines and related synthetic derivatives.
Cancer Treat. Rep. 70, 51-63.
Yuki, K., Miyauchi, T., Kakinuma, Y., Murakoshi, N., Suzuki, T., Hayashi, J., Goto, K. amd Yamaguchi, I. (2000)Mitochondrial dysfunction increases expression of endothelin-1 and induces apoptosis through caspase-3 activation in rat cardiomyocytes in vitro. J Cardiovasc Pharmacol.
36,S205-8.
Zolk, O., Quattek, J., Seeland, U., El-Armouche, A., Eschenhagen, T. and Bohm, M. (2002)Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2)27 rats. Cardiovasc
Res. 53,363-71.
Zsary, A., Szucs, S., Schneider, T., Rosta, A., Sarman, P., Fenyvesi, T. and Karadi, I. (2002)Role of endothelin-1 in the development of a special type of cardiomyopathy. Clin Sci (Lond). 48,272S-275S.
Zunino, F., Pratesi, G. and Perego, P. (2001) Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs. Biochem Pharmacol 61,933-938.